Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS

Thermally-Activated Delayed Fluorescence Nanoparticle Assemblies for Photodynamic Therapy

Descripción del proyecto

Tratamiento de precisión contra el cáncer

La terapia fotodinámica (TFD) es un tratamiento mínimamente invasivo contra el cáncer que combina la luz de un láser con tintes fotosensibilizantes para destruir las células cancerosas. Las reacciones fotoquímicas conducen a la generación de especies reactivas del oxígeno que provocan la apoptosis de las células cancerosas. A pesar de lo prometedor de la TFD, los avances han sido limitados y solo se ha aprobado el uso clínico de unos pocos colorantes. Con el apoyo de las Acciones Marie Skłodowska-Curie, el equipo del proyecto TADF-PDT introducirá una nueva clase de colorantes basados en la fluorescencia retardada activada térmicamente (TADF, por sus siglas en inglés). Estos materiales TADF eficientes se administrarán mediante vesículas extracelulares biocompatibles, lo que ofrecerá una estrategia de nueva generación para un tratamiento contra el cáncer más seguro y selectivo.

Objetivo

Photodynamic Therapy (PDT) is a non-invasive cancer treatment that uses light-activated, photosensitising dyes to generate highly reactive oxygen species (ROS) within a localised biological environment, leading to the destruction of cancer cells, while sparing surrounding healthy tissue. The PDT process comprises two stages: administration of a dye, followed by irradiation with light. Since ROS is only generated at the light-activated sites, tissue destruction is highly localised and side effects are significantly reduced. The potential for PDT is clear. However, for all this potential, widespread adoption has stagnated: only three dyes have been approved for cancer treatment globally, while the dye most commonly studied in clinical trials - Photofrin - is a statistical mixture of oligomeric porphyrins. Dye design for many years has focussed on porphyrins derived from Photofrin, and more recently phosphorescent ruthenium(II) polypyridyl complexes. However, in this proposal, a new design strategy is proposed: thermally-activated delayed fluorescence (TADF) dyes are the targets of interest. These are all-organic compounds that have small singlet-triplet energy gaps, which causes them to undergo rapid intersystem crossing and reverse intersystem crossing between the singlet and triplet states. By accessing the triplet state, they can readily generate singlet oxygen, which is one form of ROS, marking their potential for PDT. These compounds have been widely used organic device applications, but their uses in biological applications such as imaging and particularly PDT are much less. This proposal addresses this gap, using novel, cationic, near-IR emitting, TADF dyes. Their delivery to cells will be achieved using biocompatible, Extracellular Vesicles (EVs), which have been shown to be improved PDT delivery agents over other methods.

Ámbito científico (EuroSciVoc)

Palabras clave

Programa(s)

Tema(s)

Régimen de financiación

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

Ver todos los proyectos financiados en el marco de este régimen de financiación

Convocatoria de propuestas

(se abrirá en una nueva ventana) HORIZON-MSCA-2024-PF-01

Ver todos los proyectos financiados en el marco de esta convocatoria

Coordinador

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Aportación neta de la UEn
€ 260 347,92
Dirección
WELLINGTON SQUARE UNIVERSITY OFFICES
OX1 2JD Oxford
Reino Unido
Región
South East (England) Berkshire, Buckinghamshire and Oxfordshire Oxfordshire
Tipo de actividad
Higher or Secondary Education Establishments
Enlaces
Coste total
Sin datos